Business
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
REDWOOD CITY, Calif., May 05, 2025--Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
About this update from Exicure, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2431,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/a8b93df7a216e3185e139b87dbf37b0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sc5oOHeHgcX8pL1pLEOSnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a8b93df7a216e3185e139b87dbf37b0e","width":960,"height":237},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/rIzGs2.CcaeeZqAXNSRj4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a8b93df7a216e3185e139b87dbf37b0e","width":1200,"height":296}},"lazy":false},{"type":"text","content":"Topline results expected H2 2025","length":32,"tagName":"p","attribs":{}},{"type":"text","content":"REDWOOD CITY, Calif., May 05, 2025--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT).","length":455,"tagName":"p"},{"type":"text","content":"The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukapheresis for use in ASCT. Topline results from the study are expected in Fall 2025.","length":343,"tagName":"p"},{"type":"text","content":""Efficient hematopoietic progenitor cell mobilization is critical for successful hematopoietic cell transplantation. Inadequate mobilization can lead to delayed transplant, multiple rounds of apheresis, and increased costs—all of which increase the burden on patients and healthcare systems," said Jack Khouri, MD, FACP, hematologist at Cleveland Clinic and primary investigator on the trial. "GPC-100 could be transformative for patients and providers alike. We have seen effective and efficient mobilization with GPC-100 in combination with G-CSF and propranolol in our multiple myeloma patients, wi...